Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTAHIST vs EMBOLEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Low molecular weight heparin that potentiates antithrombin III, inhibiting factor Xa and factor IIa, thereby preventing thrombus formation.
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
Prophylaxis of deep vein thrombosis (DVT) in surgical patients,Treatment of DVT,Treatment of pulmonary embolism,Prophylaxis of thromboembolic complications in medical patients
1.34 mg (one capsule) orally twice daily.
Embolectomy with intra-arterial streptokinase: 250,000 IU loading dose over 30 minutes followed by 100,000 IU/hour for up to 72 hours. Alternatively, mechanical thrombectomy without thrombolytic.
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
2-3 hours (terminal half-life in healthy adults); prolonged in hepatic impairment and elderly.
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Primarily metabolized by desulfation and depolymerization in the liver; partial renal excretion.
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Renal: ~50% (10% as unchanged drug, 40% as inactive metabolites); Biliary/fecal: ~50% (primarily as metabolites).
92% bound to albumin.
99% (primarily to albumin).
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
0.1-0.2 L/kg (low, indicating limited extravascular distribution primarily in blood).
Oral: 68% ± 12% due to first-pass metabolism.
Oral: 60-75% (first-pass metabolism); Rectal: ~80%. IV: 100%.
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
No specific dose adjustment for renal impairment; use caution in severe renal impairment (Cr Cl <30 m L/min) due to increased bleeding risk.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
No specific adjustment for Child-Pugh class; use caution in severe hepatic impairment due to coagulopathy.
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
Not established; use only if benefit outweighs risk, with careful monitoring.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
Increased risk of bleeding; consider lower doses and shorter infusion durations. No specific dosing guidelines; use clinical judgment.
None.
Spinal or epidural hematomas may occur in patients receiving low molecular weight heparins and undergoing neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis.
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
Risk of spinal/epidural hematoma with neuraxial interventions; increased risk of bleeding; heparin-induced thrombocytopenia (HIT); renal impairment; elderly; pregnancy.
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
Hypersensitivity to heparin or pork products,Active major bleeding,History of heparin-induced thrombocytopenia (HIT),Known bleeding disorder,Severe uncontrolled hypertension
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
Avoid alcohol; may increase risk of GI bleeding. No significant food interactions beyond GI irritation; taking with food may slow absorption but does not affect efficacy.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
Embolex (certoparin) is a low molecular weight heparin; no evidence of teratogenicity in animal studies. First trimester: Use only if clearly needed; no known fetal risk. Second and third trimesters: May be used; risk of bleeding in mother/fetus. Avoid near delivery due to risk of maternal hemorrhage and epidural hematoma.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
Excretion into human milk is unknown; low molecular weight heparins are unlikely to be absorbed by infant. M/P ratio not available. Use with caution in breastfeeding women.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
Pregnancy increases plasma volume and renal clearance; may require higher doses to achieve therapeutic anti-Xa levels. Monitor anti-Xa levels and adjust dose accordingly. No standard dose adjustment; individualize based on weight and anti-Xa monitoring.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
EMBOLEX (meloxicam) is an NSAID with preferential COX-2 inhibition; use lowest effective dose for shortest duration to minimize GI and cardiovascular risks. Contraindicated in patients with active peptic ulcer disease, recent GI bleeding, or history of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs. Monitor renal function in elderly, dehydrated, or those on diuretics/ACE inhibitors. Not recommended for perioperative pain in CABG surgery.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, coffee-ground vomit) or cardiovascular symptoms (chest pain, shortness of breath) immediately.,Do not take with other NSAIDs (including over-the-counter ibuprofen or naproxen).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTAHIST vs EMBOLEX, answered by our medical review team.
ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. EMBOLEX is a Low Molecular Weight Heparin that works by Low molecular weight heparin that potentiates antithrombin III, inhibiting factor Xa and factor IIa, thereby preventing thrombus formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTAHIST and EMBOLEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. The standard adult dose of EMBOLEX is: Embolectomy with intra-arterial streptokinase: 250,000 IU loading dose over 30 minutes followed by 100,000 IU/hour for up to 72 hours. Alternatively, mechanical thrombectomy without thrombolytic.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTAHIST and EMBOLEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. EMBOLEX is classified as Category C. Embolex (certoparin) is a low molecular weight heparin; no evidence of teratogenicity in animal studies. First trimester: Use only if clearly needed; no known fetal risk. Second an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.